Key facts
- EG 427’s last known valuation is $123.9M (Feb 2025).
- It has raised $48.9M; the latest was Later Stage VC ($27.9M) in Feb 2025.
- Notable investors include Bpifrance, Andera Partners, Cohesion Bureau, David Lamond, Paris Biotech Sante — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for EG 427
- ·The full record, as it builds
Funding rounds
No funding rounds for EG 427 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EG 427
Developer of a pinpoint gene therapy designed to cure spinal cord injury-related disorders. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 23
- Website
- eg427.com/
- Ownership
- Privately Held (backing)
EG 427 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EG 427 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EG 427 in its N-PORT filings yet. We sweep new filings monthly.